

08-27-01

Atty. Docket No.: 9409/2023C

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Samson et al	Examiner:	Not yet assigned
Serial No.:	Not yet assigned	Group Art Unit:	Not yet assigned
Filed:	August 24, 2001	Conf. No.:	Not yet assigned
Ref. No.:	9409/2023C		
Entitled:	"Active and Inactive CC-Chemokine Receptor and Nucleic Acid Molecules Encoding Said Receptor"		

CERTIFICATE OF EXPRESS MAILING

I hereby certify that the papers attached hereto are being deposited with the United States Postal Service using Express Mail to Addressee service, **Express Mail No. EL728730750US** on this date, August 24, 2001, postage prepaid under 37 C.F.R. Section 1.10 in an envelope addressed to Box Patent Application Commissioner for Patents, Washington, D.C. 20231.

Kathleen M. Williams

Name of Person Mailing Paper

Signature of Person Mailing Paper

Box: Patent Application
Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER

Enclosed for filing the above-identified patent application, please find the following documents:

1. New Patent Application Transmittal (3 pages);
2. Patent Application Specification, (49 pages);
3. (14) sheets of informal drawings;
4. Application Data Sheet (3 pages);
5. Preliminary Amendment (4 pages) including marked up version of page 1 of Specification showing changes being made (2 pages);
6. Copy of Declaration and Power of Attorney from Parent Application U.S.S.N. 09/626,939 (4 pages);
7. Paper copy of Sequence Listing (15 pages);
8. Check in the amount of \$355.00; and
9. Return Post-Card.

The Commissioner for Patents is hereby authorized to charge any additional fees or credit any overpayment in the total fees to Deposit Account No. 16-0085, Reference 9409/2023C. A duplicate of this transmittal letter is enclosed for this purpose.

Respectfully submitted,

Date: August 24, 2001

Name: Kathleen M. Williams
Registration No.: 34,380
Palmer & Dodge LLP
One Beacon Street
Boston, MA 02108
Tel: 617-573-0667

NEW UNITED STATES UTILITY PATENT APPLICATION TRANSMITTAL

Atty. Docket No.: 9409/2023C

CERTIFICATE OF MAILING UNDER 37 CFR 1.10

I hereby certify that the paper (and any paper or fee referred to as being enclosed) is being deposited with the United States Postal Service using Express Mail to Addressee Service, under 37 C.F.R. Section 1.10, **Express Mail Label No. EL728730750US** on this date, **August 24, 2001**, postage prepaid, in an envelope addressed to Box: Patent Application, Commissioner for Patents, Washington, D.C. 20231.

Kathleen M. Williams

Name of Person Mailing Paper

Signature of Person Mailing Paper

Commissioner for Patents
Box Patent Application
Washington, D.C. 20231

Enclosed herewith is a new patent application of:

First Named Inventor (or application identifier): Michel Samson

Title of Invention: Active and Inactive CC-Chemokine Receptor and Nucleic Acid Molecules
Encoding Said Receptor

Type:

- ☐ New
☐ Continuation of: _____
☐ Continuation-in-Part of: _____
☒ Divisional of: U.S.S.N. 09/626,939 filed July 27, 2000

and includes the following papers:

- ☒ Specification 49 pages (including specification, claims, abstract)/16 claims (1 independent) after Preliminary Amendment
- ☒ Declaration/Power of Attorney is:
☒ attached ☒ executed ☐ unexecuted
☐ NOT included, but deferred under 37 C.F.R. § 1.53(f).
- ☒ 14 Distinct sheets of ☐ Formal ☒ Informal Drawings
- ☒ Preliminary Amendment.
- ☐ Information Disclosure Statement
☐ Form 1449
☐ A copy of each cited prior art reference
- ☐ Assignment with Recordation Cover Sheet.
- ☒ Priority is hereby claimed under 35 U.S.C. § 119 based upon the following application(s):

Country	Application Number	Date of Filing (day, month, year)
EP	EP 96870021.1	1, March, 1996
EP	EP 96870102.9	6, August, 1996

Atty. Docket No.: 9409/2023C

8. ☒ Priority is hereby claimed under 35 U.S.C. § 121 based upon the following application(s):

Country	Application Number	Date of Filing (day, month, year)
US	09/626,939	27, July, 2000
<input checked="" type="checkbox"/> Priority is hereby claimed under 35 U.S.C. § 120 based upon the following application(s):		
US	08/833,752	9, April 1997

9. ☐ Priority document(s).
10. ☐ Statement of Small Entity Status, Pursuant to 37 C.F.R. § 1.27.
11. ☐ Microfiche Computer Program (Appendix).
12. ☒ Nucleotide and/or Amino Acid Sequence Submission.
☒ Request for transfer of computer readable copy from 09/626,939 to present application.
☐ Paper Copy (identical to computer copy).
☐ Statement verifying identity of above copies.

13. ☐ Request for Non-Publication and Certification under 35 USC 122 (b)(2)(B)(i)

14. Calculation of Fees:

FEES FOR	TOTAL CLAIMS	EXCESS CLAIMS	FEE	AMOUNT DUE
Basic Filing Fee (37 C.F.R. § 1.16(a))				\$710.00
Total Claims in Excess of 20 (37 C.F.R. § 1.16(c))	16	0	\$18.00	0.00
Independent Claims in Excess of 3 (37 C.F.R. § 1.16(b))	1	0	\$80.00	0.00
Multiple Dependent Claims (37 C.F.R. § 1.16(d))	NO		\$270.00	
Subtotal - Filing Fee Due				\$710.00
Reduction by 50%, if Small Entity (37 C.F.R. §§ 1.9, 1.27, 1.28)	MULTIPLY BY 0.50			\$355.00
TOTAL FILING FEE DUE				
Assignment Recordation Fee (if applicable) (37 C.F.R. § 1.21(h))	0		\$40.00	
GRAND TOTAL DUE				\$355.00

15. PAYMENT is:

- ☒ included in the amount of \$355.00 by our enclosed check. The Commissioner is hereby authorized to charge any deficiencies in the fees to Deposit Account 16-0085, Ref. 9409/2023C.
- ☐ not included, but deferred under 37 C.F.R. § 1.53(f).

Atty. Docket No.: 9409/2023C

- Respectfully submitted,

By:

Registration No.: 34,380

[illegible]

PATENT

METHODS FOR IDENTIFYING COMPOUNDS WHICH BIND THE ACTIVE CCR5
CHEMOKINE RECEPTOR-

~~This is a continuation application under 37 CFR 1.53 OF U.S. Patent Application No.~~
~~08/810,028 filed March 3, 1997.~~

This application claims priority under 35 U.S.C. § 120 to U.S. Patent Application Serial No. 09/626,939, filed July 27, 2000, which claims priority under 35 U.S.C. § 120 to U.S. Patent Application Serial No. 08/833,752, filed April 9, 1997, which claims priority under 35 U.S.C. § 119(a)-(d) to EP 96870021.1, filed March 1, 1996, and EP 96870102.9, filed August 6, 1996.

The present invention concerns new peptides and the nucleic acid molecules encoding said peptides, the vector comprising said nucleic acid molecules, the cells transformed by said vector, inhibitors directed against said peptides or said nucleic acid molecules, a pharmaceutical composition and a diagnostic and/or dosage device comprising said products, and non human transgenic animals expressing the peptides according to the invention or the nucleic acid molecules encoding said peptides.

The invention further provides a method for determining ligand binding, detecting expression, screening for drugs binding specifically to said peptides and treatments involving the peptides or the nucleic acid molecules according to the invention.

Technological Background of the Art

Chemotactic cytokines, or chemokines, are small signalling proteins that can be divided in two subfamilies (CC- and CXC-chemokines) depending on the relative position of the first two conserved cysteines. Interleukin 8 (IL-8) is the most studied of these proteins, but a large number of chemokines (Regulated on Activation Normal T-cell Expressed and Secreted

093923-03401
04230" 3226650